JP2017519723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519723A5 JP2017519723A5 JP2016565203A JP2016565203A JP2017519723A5 JP 2017519723 A5 JP2017519723 A5 JP 2017519723A5 JP 2016565203 A JP2016565203 A JP 2016565203A JP 2016565203 A JP2016565203 A JP 2016565203A JP 2017519723 A5 JP2017519723 A5 JP 2017519723A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- autoimmune
- cells
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 4
- 229940123208 Biguanide Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 210000000068 Th17 cell Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000024389 cytopenia Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140051261 | 2014-04-29 | ||
| KR10-2014-0051261 | 2014-04-29 | ||
| PCT/KR2015/004299 WO2015167243A1 (ko) | 2014-04-29 | 2015-04-29 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
| KR10-2015-0060182 | 2015-04-29 | ||
| KR1020150060182A KR101705446B1 (ko) | 2014-04-29 | 2015-04-29 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519723A JP2017519723A (ja) | 2017-07-20 |
| JP2017519723A5 true JP2017519723A5 (enExample) | 2018-05-17 |
| JP6462002B2 JP6462002B2 (ja) | 2019-01-30 |
Family
ID=54601170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565203A Active JP6462002B2 (ja) | 2014-04-29 | 2015-04-29 | 免疫疾患治療効果を有する新規化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170114008A1 (enExample) |
| EP (1) | EP3130582B8 (enExample) |
| JP (1) | JP6462002B2 (enExample) |
| KR (1) | KR101705446B1 (enExample) |
| CN (2) | CN111407753A (enExample) |
| AU (1) | AU2015254037B2 (enExample) |
| CA (1) | CA2946516C (enExample) |
| ES (1) | ES2702337T3 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101949451B1 (ko) | 2015-10-13 | 2019-05-10 | 주식회사 이노파마스크린 | 염증성 장 질환 및 아토피 피부염 치료용 조성물 |
| JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. | シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用 |
| CN111566084B (zh) * | 2017-09-05 | 2022-12-20 | 北京强新生物科技有限公司 | 中枢神经系统疾病的新疗法 |
| CN118453559A (zh) | 2018-02-15 | 2024-08-09 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| WO2020049505A1 (en) | 2018-09-06 | 2020-03-12 | Innopharmascreen Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
| KR102147802B1 (ko) * | 2018-11-07 | 2020-08-25 | 가톨릭대학교 산학협력단 | 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물 |
| US20220033489A1 (en) * | 2018-12-04 | 2022-02-03 | The Children's Medical Center Corporation | Methods and compositions for treating asthma |
| KR102316961B1 (ko) * | 2020-01-29 | 2021-10-26 | 프라비바이오 주식회사 | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 |
| CN113907047B (zh) * | 2021-12-13 | 2022-03-11 | 天津医科大学总医院空港医院 | 一种自身抗原表位诱导的eam小鼠模型的建立方法 |
| CN115152700B (zh) * | 2022-06-28 | 2023-06-27 | 广东省人民医院 | 胶体锰佐剂在制备原发性干燥综合征动物模型中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4060635A (en) * | 1975-03-31 | 1977-11-29 | William H. Rorer, Inc. | Amidinoureas for treating diarrhea |
| US4183956A (en) * | 1975-11-05 | 1980-01-15 | William H. Rorer, Inc. | Method for treating gastrointestinal spasms, gastrointestinal hyperacidity and hypertensive disorders with amidinoureas |
| US8053477B2 (en) * | 2002-03-29 | 2011-11-08 | University Of Maryland, Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
| US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| CA2932121A1 (en) * | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| JP2013501057A (ja) * | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性t細胞のinvivoにおける増殖 |
| KR101136045B1 (ko) * | 2009-11-16 | 2012-04-18 | 한국화학연구원 | N1-(펜에틸)-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| KR101274981B1 (ko) | 2010-01-06 | 2013-06-18 | 한올바이오파마주식회사 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| CN103119042B (zh) | 2010-08-25 | 2016-06-01 | 株式会社新药 | 新的杂环化合物及利用其治疗炎性疾病的组合物 |
| US8796338B2 (en) * | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| KR101432246B1 (ko) * | 2011-09-20 | 2014-08-21 | 가톨릭대학교 산학협력단 | 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물 |
| CN102698266A (zh) * | 2012-05-15 | 2012-10-03 | 中国医学科学院北京协和医院 | Cd200在制备系统性红斑狼疮治疗药物中的应用 |
| KR101432892B1 (ko) * | 2012-09-17 | 2014-08-21 | 가톨릭대학교 산학협력단 | 메트포민을 이용한 루프스를 포함하는 면역질환의 예방 또는 치료용 조성물 |
| KR101613371B1 (ko) * | 2014-11-10 | 2016-04-18 | 가톨릭대학교 산학협력단 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
-
2015
- 2015-04-29 ES ES15786179T patent/ES2702337T3/es active Active
- 2015-04-29 KR KR1020150060182A patent/KR101705446B1/ko active Active
- 2015-04-29 AU AU2015254037A patent/AU2015254037B2/en active Active
- 2015-04-29 EP EP15786179.0A patent/EP3130582B8/en active Active
- 2015-04-29 CN CN202010321725.6A patent/CN111407753A/zh active Pending
- 2015-04-29 CN CN201580021720.9A patent/CN106458869A/zh active Pending
- 2015-04-29 JP JP2016565203A patent/JP6462002B2/ja active Active
- 2015-04-29 CA CA2946516A patent/CA2946516C/en active Active
-
2016
- 2016-10-31 US US15/339,410 patent/US20170114008A1/en not_active Abandoned
-
2017
- 2017-11-21 US US15/819,758 patent/US10100006B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519723A5 (enExample) | ||
| Picchianti Diamanti et al. | Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity | |
| Luchtman et al. | IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments | |
| Zhang et al. | Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo | |
| Ghoreschi et al. | T helper 17 cell heterogeneity and pathogenicity in autoimmune disease | |
| Monaghan et al. | The role of granulocyte-macrophage colony-stimulating factor in murine models of multiple sclerosis | |
| JP2016056206A5 (enExample) | ||
| JP2016530265A5 (enExample) | ||
| Song et al. | The relationship between life style, menstrual attitude and premenstrual syndrome in nursing students | |
| RU2014122546A (ru) | Способ лечения | |
| Paroli et al. | The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment | |
| WO2018151811A3 (en) | Use of tgf alpha for the treatment of diseases and disorders | |
| RU2015110635A (ru) | Лечение сосудистого заболевания и его осложнений | |
| IN2014CN04823A (enExample) | ||
| JP2013523886A5 (enExample) | ||
| JP2004536105A5 (enExample) | ||
| BRPI0516661A (pt) | epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal | |
| Khaled et al. | Adult patients with ALL treated with CD62L+ T naïve/memory-enriched T cells expressing a CD19-CAR mediate potent antitumor activity with a low toxicity profile | |
| Moseley et al. | Motor imagery for peripheral injury | |
| Volkova et al. | A study of the level of circulating cytokines in patients with atopic dermatitis | |
| Wang et al. | The Role of Oncogene in Mycobacteria-induced Antophagy in | |
| Pimenova et al. | Cytoprotective potential of monoclonal antibodies against Burkholderia pseudomallei | |
| Mozgova et al. | Cell immunity parameters in K. pneumoniae experimental generalized pyo-inflammatory process | |
| Fujimoto et al. | Splenocyte Cytokine Profile in Mouse with Oral Mucosa-sensitization and Oral-tolerization by NiSO4 | |
| Lee et al. | Clinical characteristics and prevalence of toxoplasma infection in human immunodeficiency virus-infected patients in South Korea |